← Russell 3000 cross-section

SOLV Solventum Corp

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$15.7bn
Revenue TTM
$8.3bn
Net income TTM
$1.4bn
Free cash flow
$-118m
Composite score
53.7
Sector rank
#526

Valuation

P / E
10.9
EV / EBITDA
7.9
EV / sales
2.4
FCF yield
-0.75%
Earnings yield vs 10-yr
4.43pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
17.3%
EBITDA margin
31.1%
ROE
29.9%
ROIC
21.9%
Revenue growth
-0.9%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Sales growth for the three months ended June 30, 2026 benefited by approximately $125 million due to these advanced orders. Total Company divestiture impacts include lost sales from the Company’s Purification and Filtration business that was sold in September 2025. Additional information beyond what is included in the preceding table is as follows: Second quarter 2026 results: • In the United States geographic area, both total sales and organic sales increased. Other is comprised of lost sales due to the divestiture of the Purification and Filtration business in September 2025, partially offset by sales from the December 2025 Acera acquisition. …Solventum Corp, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →